NCT05466799 - FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions

Locally Advanced Pancreatic Cancer

Interventions

DRUG

FOLFIRINOX chemotherapy

Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer

DEVICE

OncoSil™

Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance

Trial Locations (17)

31008

RECRUITING

Clínica Universidad de Navarra, Pamplona

Unknown

RECRUITING

Royal Adelaide Hospital, Adelaide

NOT_YET_RECRUITING

Epworth Healthcare, Richmond

RECRUITING

AZ Maria Middelares, Ghent

RECRUITING

San Camillo Forlanini, Rome

RECRUITING

Azienda Ospedaliera Universitaria Integrata Verona, Verona

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

RECRUITING

Hospital General Universitario Gregorio Marañón, Madrid

RECRUITING

Hospital Universitario 12 de Octobre, Madrid

RECRUITING

Hospital Universitario de Fuenlabrada, Madrid

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

NOT_YET_RECRUITING

Hospital Universitari i Politècnic La Fe, Valencia

NOT_YET_RECRUITING

Guy's Hospital, London

RECRUITING

Imperial College, London

RECRUITING

The Christie Hospital/Manchester Royal Infirmary, Manchester

RECRUITING

Freeman Hospital, Newcastle upon Tyne

RECRUITING

University Hospital Southampton, Southampton